FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 676 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim September 18, 2025 Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... September 11, 2024 Cuando necesita ayuda con responsabilidades de cuidado June 15, 2021 Stopping the spread: A revolution in how we think about metastasis October 18, 2022 Load more HOT NEWS Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... What to Know About the Different Types of Mastectomies for Breast... Can Using a Microwave Cause Cancer? FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
